公开(公告)号：US20100215677A1

公开(公告)日：2010-08-26

申请号：US12770682

申请日：2010-04-29

申请人： Peter S. Lu ,  Chamorro Somoza Diaz-Sarmiento ,  Brian Seed ,  Ramnik Xavier ,  Bryan Allen Irving

发明人： Peter S. Lu ,  Chamorro Somoza Diaz-Sarmiento ,  Brian Seed ,  Ramnik Xavier ,  Bryan Allen Irving

IPC分类号： A61K39/00 ,  G01N33/53 ,  C12N5/07 ,  A61P37/00 ,  A61P3/10 ,  A61P19/02 ,  A61P17/06 ,  A61P35/02 ,  A61P35/00 ,  A61P1/00 ,  C07K2/00 ,  C07K14/00

CPC分类号： G01N33/564 ,  G01N33/566 ,  G01N2500/02

摘要： Methods for modulating immune cell signaling are provided. In general such methods involve modulating an interaction between a PDZ protein and a PDZ ligand protein whose interaction affects the composition and/or distribution of lipid rafts in an immune cell. Modulators that enhance or inhibit such interactions are also disclosed, as well as methods of screening for such modulators.

摘要翻译： 提供了调节免疫细胞信号传导的方法。 通常，这种方法涉及调节PDZ蛋白和PDZ配体蛋白之间的相互作用，其相互作用影响免疫细胞中脂筏的组成和/或分布。 还公开了增强或抑制这种相互作用的调节剂，以及筛选这种调节剂的方法。

公开(公告)号：US20080166736A1

公开(公告)日：2008-07-10

申请号：US11674034

申请日：2007-02-12

申请人： Peter S. Lu ,  Chamorro Somoza Diaz-Sarmiento ,  Brian Seed ,  Ramnik Xavier ,  Brayan Allen Irving

发明人： Peter S. Lu ,  Chamorro Somoza Diaz-Sarmiento ,  Brian Seed ,  Ramnik Xavier ,  Brayan Allen Irving

IPC分类号： G01N33/53 ,  C12N5/00

CPC分类号： G01N33/564 ,  G01N33/566 ,  G01N2500/02

摘要： Methods for modulating immune cell signaling are provided. In general such methods involve modulating an interaction between a PDZ protein and a PDZ ligand protein whose interaction affects the composition and/or distribution of lipid rafts in an immune cell. Modulators that enhance or inhibit such interactions are also disclosed, as well as methods of screening for such modulators.

摘要翻译： 提供了调节免疫细胞信号传导的方法。 通常，这种方法涉及调节PDZ蛋白和PDZ配体蛋白之间的相互作用，其相互作用影响免疫细胞中脂筏的组成和/或分布。 还公开了增强或抑制这种相互作用的调节剂，以及筛选这种调节剂的方法。

公开(公告)号：US08993295B2

公开(公告)日：2015-03-31

申请号：US12374616

申请日：2007-07-20

申请人： Brian Seed ,  Jia Liu Wolfe ,  Glen S. Cho ,  Chia-Iun Tsai

发明人： Brian Seed ,  Jia Liu Wolfe ,  Glen S. Cho ,  Chia-Iun Tsai

IPC分类号： C12N9/96 ,  C07K16/28 ,  A61K47/48 ,  B82Y5/00 ,  C07K14/195 ,  C07K14/28 ,  C07K14/34 ,  C12N9/16 ,  A61K38/00

CPC分类号： C07K16/2803 ,  A61K38/00 ,  A61K47/6849 ,  A61K47/6889 ,  A61K47/6899 ,  B82Y5/00 ,  C07K14/195 ,  C07K14/28 ,  C07K14/34 ,  C07K2319/55 ,  C12N9/16 ,  Y02A50/471

摘要： The present invention provides methods and compositions for treating various diseases through selective killing of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population.

摘要翻译： 本发明提供了使用组合靶向方法通过选择性杀死靶细胞来治疗各种疾病的方法和组合物。 本发明的特征在于含有细胞靶向部分的原毒素融合蛋白，以及由目标细胞内或其附近天然可操作地发现的活化部分活化的可修饰的活化部分。 这些方法还包括组合使用两种或更多种治疗剂，至少包含原毒素和原毒素激活剂以靶向和破坏特定细胞群体。

公开(公告)号：US08987323B2

公开(公告)日：2015-03-24

申请号：US13158724

申请日：2011-06-13

申请人： Mengzhuang Cai ,  Qian Liu ,  Ge Xu ,  Binhua Lv ,  Brian Seed ,  Jacques Y. Roberge

发明人： Mengzhuang Cai ,  Qian Liu ,  Ge Xu ,  Binhua Lv ,  Brian Seed ,  Jacques Y. Roberge

IPC分类号： A01N43/16 ,  A61K31/35 ,  A01N43/02 ,  A61K31/335 ,  A01N43/00 ,  A61K31/33 ,  C07D315/00 ,  C07D309/10

CPC分类号： C07H1/06 ,  C07D309/10 ,  C07H7/04

摘要： Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

摘要翻译： 提供对钠依赖性葡萄糖转运体SGLT2具有抑制作用的化合物的结晶形式。 本发明还提供药物组合物，制备结晶化合物的方法，以及独立地或与其它治疗剂组合使用结晶化合物治疗受SGLT或SGLT2抑制影响的疾病和病症的方法。

公开(公告)号：US08748419B2

公开(公告)日：2014-06-10

申请号：US11763313

申请日：2007-06-14

申请人： Brian Seed ,  Jordan Mechanic

发明人： Brian Seed ,  Jordan Mechanic

IPC分类号： C07D487/04 ,  A61K31/55 ,  C07D333/20 ,  C07D307/80 ,  A61K31/135

CPC分类号： A61K31/343 ,  A61K31/135 ,  A61K31/137 ,  A61K31/381 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

摘要： Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.

摘要翻译： 提供了通过施用优选的毒蕈碱性乙酰胆碱受体M1拮抗剂，任选地与选择性毒蕈碱性乙酰胆碱受体M1拮抗剂以外的至少一种抗抑郁药来治疗肥胖症并实现所需体重减轻或预防不希望的体重增加的方法。 优选的毒蕈碱性乙酰胆碱受体M1拮抗剂，任选地可以与抗肥胖剂，例如无痛剂一起施用。 本发明还提供用于至少一种选择性毒蕈碱性乙酰胆碱受体M1拮抗剂与除选择性毒蕈碱性乙酰胆碱受体M1拮抗剂之外的至少一种抗抑郁药组合的药物组合物和试剂盒。

公开(公告)号：US20120238510A1

公开(公告)日：2012-09-20

申请号：US13158724

申请日：2011-06-13

申请人： Mengzhuang Cai ,  Qian Liu ,  Ge Xu ,  Binhua Lv ,  Brian Seed ,  Jacques Y. Roberge

发明人： Mengzhuang Cai ,  Qian Liu ,  Ge Xu ,  Binhua Lv ,  Brian Seed ,  Jacques Y. Roberge

IPC分类号： A61K31/7034 ,  C07H1/06 ,  A61P3/10 ,  A61P5/48 ,  A61P3/00 ,  A61P35/00 ,  A61P7/00 ,  A61P3/04 ,  A61P7/10 ,  A61P3/06 ,  A61P9/04 ,  A61P9/10 ,  C07H7/04 ,  A61P9/12

CPC分类号： C07H1/06 ,  C07D309/10 ,  C07H7/04

摘要： Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

摘要翻译： 提供对钠依赖性葡萄糖转运体SGLT2具有抑制作用的化合物的结晶形式。 本发明还提供药物组合物，制备结晶化合物的方法，以及独立地或与其它治疗剂组合使用结晶化合物治疗受SGLT或SGLT2抑制影响的疾病和病症的方法。

公开(公告)号：US20080182802A1

公开(公告)日：2008-07-31

申请号：US11964493

申请日：2007-12-26

申请人： Michael J. Hadd ,  Yuanwei Chen ,  Yan Feng ,  Sengen Sen ,  Brian Seed

发明人： Michael J. Hadd ,  Yuanwei Chen ,  Yan Feng ,  Sengen Sen ,  Brian Seed

IPC分类号： A61K31/7048 ,  C07H17/04 ,  A61P3/10 ,  A61P3/04

CPC分类号： C07H17/04

摘要： Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

摘要翻译： 提供对钠依赖性葡萄糖转运蛋白SGLT具有抑制作用的化合物。 本发明还提供药物组合物，制备化合物的方法，合成中间体，以及独立地或与其它治疗剂组合使用化合物治疗受SGLT抑制影响的疾病和病症的方法。

公开(公告)号：US07109206B2

公开(公告)日：2006-09-19

申请号：US09735024

申请日：2000-12-12

申请人： Brian Seed ,  John C. Seed

发明人： Brian Seed ,  John C. Seed

IPC分类号： A61K31/505 ,  A61K31/44 ,  A61K31/40 ,  A61K31/35 ,  A61K31/21

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/60 ,  A61K31/785 ,  Y10S514/824 ,  A61K2300/00

摘要： Disclosed are methods and compositions for reducing coronary artery stenosis, restoring blood flow to infarcted myocardium, improving myocardial perfusion, reducing heart attacks or other adverse cardiovascular events, or treating symptoms of inadequate myocardial function in a mammal involving administering to the mammal (a) a compound that includes eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol-lowering therapeutic, combined with dietary restrictions (resulting in aggressive loading of marine lipids), whereby a serum LDL concentration of less than 75 mg/dl (and preferably less than 55 mg/dl) is achieved. One particular method involves administering to the mammal a combination that includes (a) a compound that includes an eicosapentaeneoic or docosahexaeneoic acid (for example, a marine lipid) and (b) a cholesterol synthesis or transfer inhibitor, and which may also optionally include aspirin and/or niacin. The methods and compositions of the invention may also further include a bile acid sequestrant and/or buspirone. Also disclosed are methods for treating heart disease that involve administration of buspirone.

公开(公告)号：US20060088898A1

公开(公告)日：2006-04-27

申请号：US10521634

申请日：2003-08-01

申请人： Brian Seed ,  Yi Yang

发明人： Brian Seed ,  Yi Yang

IPC分类号： C12Q1/62 ,  A01K67/027 ,  C12N5/06

CPC分类号： C12N15/8509 ,  A01K2217/072 ,  A01K2217/075 ,  C12N15/907 ,  C12N2800/30 ,  G01N33/5011 ,  G01N33/5088

摘要： The present invention features novel methods for generating cell lines and mammals with site-specific genetic modifications of interest. The methods involve homologous recombination between an artificial chromosome having a modification of interest and an endogenous chromosome of a cell. The resulting modified cells can be used in standard methods to generate genetically modified mammals. These mammals can be used in a variety of screening methods to identify compounds useful for the treatment or prevention of disease. Additionally, cells that have been modified to eliminate a mutation associated with a disease can be transplanted into patients for the treatment of a disease.

公开(公告)号：US06410014B1

公开(公告)日：2002-06-25

申请号：US09333636

申请日：1999-06-15

申请人： Brian Seed ,  Charles Romeo ,  Waldemar Kolanus

发明人： Brian Seed ,  Charles Romeo ,  Waldemar Kolanus

IPC分类号： A61K4800

CPC分类号： A61K35/17 ,  A61K35/13 ,  A61K35/15 ,  A61K35/28 ,  A61K38/00 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70535 ,  C07K19/00 ,  C07K2319/00 ,  C12N9/1205

摘要： Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.